Chee Conley 4
4 · Syros Pharmaceuticals, Inc. · Filed Apr 4, 2023
Insider Transaction Report
Form 4
Chee Conley
Chief Commercial Officer
Transactions
- Exercise/Conversion
Common Stock
2023-03-31+2,000→ 2,000 total - Tax Payment
Common Stock
2023-04-03$2.58/sh−658$1,698→ 1,342 total - Exercise/Conversion
Restricted Stock Units
2023-03-31−2,000→ 6,000 total→ Common Stock (2,000 underlying)
Footnotes (5)
- [F1]Represents shares of common stock received upon vesting of a restricted stock unit award.
- [F2]On September 16, 2022, the issuer effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
- [F3]Represents shares used to cover tax withholding on a restricted stock unit release.
- [F4]Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
- [F5]Represents a restricted stock unit award granted on February 15, 2022. These restricted stock units vest in four equal annual installments commencing on March 31, 2023.